跳至主要内容
临床试验/NCT05433220
NCT05433220招募中不适用

PRagmatic Trial Of Messaging to Providers About Treatment of Heart Failure (PROMPT-HF) at Inova

Inova Health Care Services2 个研究点 分布在 1 个国家目标入组 5,000 人开始时间: 2022年8月25日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
5,000
试验地点
2
主要终点
Increased use of GDMT in patients with Heart Failure with Reduced Ejection Fraction

研究概览

简要总结

A randomized, single-blind intervention trial to test the comparative effectiveness of an electronic health record best practice advisory system that informs clinicians of guideline-indicated and FDA-approved heart failure medications currently not prescribed to their patients with heart failure versus usual care (no alert and how things are done currently). The purpose of the alert is to stimulate appropriate medication prescription for patients with heart failure and a reduced ejection fraction. This will be done across outpatient Inova clinics and at the five Inova hospitals.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age>18 Years
  • Seen by a Cardiologist in an Inova clinic or Inova hospital setting
  • Left Ventricular Ejection Fraction ≤40%

排除标准

  • Opted out of EHR-based research
  • Hospice care
  • Already receiving maximally titrated doses of each of the four classes of evidence- based HFrEF medical therapy
  • Prior heart transplant

研究组 & 干预措施

Alert when provider is entering orders

Experimental

干预措施: Best Practice Advisory using Electronic Health Record (Other)

No alert, usual care

No Intervention

结局指标

主要结局

Increased use of GDMT in patients with Heart Failure with Reduced Ejection Fraction

时间窗: 30 days after randomization

The primary outcome for the trial will be the proportion of patients with HFrEF who have an increase in the number of prescribed evidence-based therapies for HFrEF (beta-blockers, ACE-I/ARB/ARNI, MRA, SGLT2i) 30 days after randomization.

次要结局

  • All-cause hospitalization and all-cause mortality at 30 days(30 days)
  • All-cause hospitalization and all-cause mortality at 90 days(90 days)
  • All-cause hospitalization and all-cause mortality at 180 days(180 days)
  • All-cause hospitalization and all-cause mortality at 1 year(1 year)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验